Exploiting the 2‑Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery by Pasquale Linciano (4426435)

“…In particular, compound <b>4m</b>, a biphenyl-thiadiazole-2,5-diamine with IC₅₀ = 16 μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC₅₀ value. …”

Exploiting the 2‑Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery by Pasquale Linciano (4426435)

“…In particular, compound <b>4m</b>, a biphenyl-thiadiazole-2,5-diamine with IC₅₀ = 16 μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC₅₀ value. …”

Exploiting the 2‑Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery by Pasquale Linciano (4426435)

“…In particular, compound <b>4m</b>, a biphenyl-thiadiazole-2,5-diamine with IC₅₀ = 16 μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC₅₀ value. …”

Exploiting the 2‑Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery by Pasquale Linciano (4426435)

“…In particular, compound <b>4m</b>, a biphenyl-thiadiazole-2,5-diamine with IC₅₀ = 16 μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC₅₀ value. …”

Exploiting the 2‑Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery by Pasquale Linciano (4426435)

“…In particular, compound <b>4m</b>, a biphenyl-thiadiazole-2,5-diamine with IC₅₀ = 16 μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC₅₀ value. …”

Exploiting the 2‑Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery by Pasquale Linciano (4426435)

“…In particular, compound <b>4m</b>, a biphenyl-thiadiazole-2,5-diamine with IC₅₀ = 16 μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC₅₀ value. …”

Exploiting the 2‑Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery by Pasquale Linciano (4426435)

“…In particular, compound <b>4m</b>, a biphenyl-thiadiazole-2,5-diamine with IC₅₀ = 16 μM, was able to potentiate the antitrypanosomal activity of the dihydrofolate reductase inhibitor methotrexate (MTX) with a 4.1-fold decrease of the EC₅₀ value. …”

Fig 1 - by Kushank Bajaj (7421042)

“…The climate impact on national food supply based on consumption and domestic perspective under additional 2°C global warming. We compare the crop-aggregated domestic climate impact (sensitivity of crop yields of wheat, maize, and rice to future warming) (x-axis, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0314722#pone.0314722.s009" target="_blank">S4 Fig</a>) to the consumption impact on calorie supply i.e., climate impacts on both domestic and overseas supplying regions (y-axis, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0314722#pone.0314722.s009" target="_blank">S4 Fig</a>). …”

The weak activator Nrf1β/LCR-F1 is negatively regulated by its CTD. by Yiguo Zhang (512679)

“…The data are shown as a fold change (mean ± S.D), and significant increases ($, p<0.05 and $$, p<0.001, n = 9) and decreases (*p<0.05, **p<0.001, n = 9) are indicated, relatively to the background value from transfection with an empty pcDNA3 control vector alone (<i>C</i>). …”

Model results of the effects of developmental interactions on transient alpha diversity and stationary beta diversity in an environment discretized into 25 patches (see S9 Fig). by Fernando W. Rossine (8599806)

“…In a stochastic environment with mean starvation time = 430 hours (symbol with black boundary in <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3000642#pbio.3000642.g005" target="_blank">Fig 5E</a>), the mean extinction time decreases (decreased transient alpha diversity), but the variability in the winner across patches increases compared to segregated development (increased stationary beta diversity). …”

Hunchback directly represses <i>eve3+7</i>. by Ben J. Vincent (5727950)

“…Data is taken from timepoint 4. (C) 2D projection of a representative wild-type embryo expressing <i>eve3+7 lacZ</i>. …”

Effects of various parameters in spreading of cooperative behavior. by Sourav Roy (389598)

“…<p>Subfigure (a) reveals two contrasting scenarios, where the cooperators decrease with the increment of the mutation rate <i>μ</i>. …”

The Gc fusion loops. by Pablo Guardado-Calvo (2325709)

“…VLPs were incubated with liposomes labeled with a fluorescent dye (DPH, see <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1005813#sec013" target="_blank">Materials and Methods</a>) at pH 7.4 or 5.5. …”

Table_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

DataSheet_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

Table_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

Table_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

DataSheet_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

Table_3_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”

Table_3_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

“…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”